93 related articles for article (PubMed ID: 1177741)
1. [Comparative clinico-pharmacological studies on the lipid lowering effect of EMO 100 and clofibrate].
Leopold G; Simane Z; Stoll KD; Breuer J
Med Welt; 1975 Aug; 6(35):1542-4. PubMed ID: 1177741
[No Abstract] [Full Text] [Related]
2. Proceedings: Potentiating of lipid lowering activity of clofibrate by combining with low doses of 3-pyridylcarbinol in rats.
Simane Z; Nowak H
Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R94. PubMed ID: 4276652
[No Abstract] [Full Text] [Related]
3. Potential hypolipidemic agents. XIII. Synthesis and plasma lipid-lowering properties of some acetals derived from 3-pyridylmethanol or nicotinaldehyde.
Bondesson G; Hedbom C; Magnusson O; Stjernström NE
Acta Pharm Suec; 1976; 13(1):1-8. PubMed ID: 1258658
[No Abstract] [Full Text] [Related]
4. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.
Ginocchio AV; Metz G
Arzneimittelforschung; 1980; 30(11b):2032-4. PubMed ID: 7194054
[TBL] [Abstract][Full Text] [Related]
5. [Cholesterol and lipid lowering effects and vascular action of p-chlororphenoxy-alpha-isobutyrate of 3-hydroxymethyl-pyridine-hydrochloric acid (clofinol)].
Marmo E; Caputi AP; Vacca C; Imperatore A; Cataldi S
Clin Ter; 1974 Mar; 68(6):519-67. PubMed ID: 4831379
[No Abstract] [Full Text] [Related]
6. Hypolipemic activity of clofibrate-related compounds.
Metz G; Specker M
Arzneimittelforschung; 1975 Nov; 25(11):1686-92. PubMed ID: 1243074
[TBL] [Abstract][Full Text] [Related]
7. Potential hypolipidemic agents. XII. Synthesis and plasma lipid-lowering properties of some 3-pyridylmethyl ethers.
Bondesson G; Hedbom C; Magnusson O; Stjernström NE
Acta Pharm Suec; 1975; 12(5-6):445-54. PubMed ID: 1217497
[No Abstract] [Full Text] [Related]
8. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
Sterner W; Schultz A
Arzneimittelforschung; 1974 Dec; 24(12):1990-2. PubMed ID: 4480360
[No Abstract] [Full Text] [Related]
9. Hypolipemic activity of clofibrate-related compounds. 2nd Communication.
Metz G; Specker M
Arzneimittelforschung; 1977 Jul; 27(7):1421-4. PubMed ID: 578466
[TBL] [Abstract][Full Text] [Related]
10. [Clinical testing of a combination of clofibrate and beta-pyridylcarbinol in an unusual dosis relation].
Mann S; Maisenbacher HJ
Z Allgemeinmed; 1975 Aug; 51(24):1066-71. PubMed ID: 1101545
[No Abstract] [Full Text] [Related]
11. Comparison of the lipid-lowering effect of clofibrate, and of clofibrate plus beta-pyridylcarbinol.
Graham L; Mulcahy R; Hickey N
Atherosclerosis; 1977 Aug; 27(4):487-92. PubMed ID: 884003
[TBL] [Abstract][Full Text] [Related]
12. [Effect of ethofibrate [2-(nicotinoyloxy)ethyl-p-chlorophenoxyisobutyrate] on lipid metabolism. I. Effect on blood lipids in normal and hyperlipemic rats].
Maroto ML; Priego JG; Piña M; Catalán RE
Arch Farmacol Toxicol; 1978 Apr; 4(1):25-7. PubMed ID: 697396
[No Abstract] [Full Text] [Related]
13. The hypolipidaemic effect of gemfibrozil (CI-719) in laboratory animals.
Rodney G; Uhlendorf P; Maxwell RE
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):6-10. PubMed ID: 828263
[No Abstract] [Full Text] [Related]
14. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
Davies JE; Kellett DN
Arzneimittelforschung; 1980; 30(11b):2035-7. PubMed ID: 7194055
[TBL] [Abstract][Full Text] [Related]
15. Effect of clofibrate on plasma lipid concentration and liver malic enzyme gene expression in rats with experimental chronic renal failure.
Korczyńska J; Stelmańska E; Nieweglowski T; Szołkiewicz M; Rutkowski B; Swierczyński J
Pol J Pharmacol; 2000; 52(4):291-7. PubMed ID: 11345485
[TBL] [Abstract][Full Text] [Related]
16. Effect of probucol on triton induced hyperlipidemias in CFY rats.
Krishnamurthy A; Thapar GS; Shridhar DR
Artery; 1985; 13(2):87-94. PubMed ID: 4084069
[TBL] [Abstract][Full Text] [Related]
17. [Does magnesium-orotate improve the effect of lipid lowering drugs?].
Irsigler K; Flegel U; Kühn P; Schubert H; Iván E; Biro L; Székely L
Int J Clin Pharmacol; 1973 Aug; 8(1):85-95. PubMed ID: 4727450
[No Abstract] [Full Text] [Related]
18. [Comparative effects of clofibrate and tiadenol on the metabolism of cholesterol in rats. II. Comparative action of clofibrate and tiadenol on biliary and fecal excretion of cholesterol and its metabolites in rats].
Fredj G; Clenet M; Rousselet F
Ann Pharm Fr; 1986; 44(5):347-54. PubMed ID: 3579157
[No Abstract] [Full Text] [Related]
19. Mechanism of the hypolipemic effect of clofibrate in postabsorptive man.
Wolfe BM; Kane JP; Havel RJ; Brewster HP
J Clin Invest; 1973 Sep; 52(9):2146-59. PubMed ID: 4353773
[TBL] [Abstract][Full Text] [Related]
20. Potential hypolipidemic agents. IX. Heterocyclic compouns related to methyl clofenapate.
Gronowitz S; Svenson R; Bondesson G; Magnusson O; Stjernström NE
Acta Pharm Suec; 1974 Jun; 11(3):211-24. PubMed ID: 4839733
[No Abstract] [Full Text] [Related]
[Next] [New Search]
